[Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer]

Ten I Godai; Takashi Oshima; Masakatsu Numata; Michiko Fukahori; Tsutomu Sato; Hirochika Makino; Shoichi Fujii; Yasushi Rino; Munetaka Masuda; Toshio Imada; Chikara Kunisaki

[Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer]

Gan To Kagaku Ryoho. 2011 Jun;38(6):945-9.

[Article in Japanese]

Authors

Ten I Godai¹, Takashi Oshima, Masakatsu Numata, Michiko Fukahori, Tsutomu Sato, Hirochika Makino, Shoichi Fujii, Yasushi Rino, Munetaka Masuda, Toshio Imada, Chikara Kunisaki

Affiliation

¹ Dept. of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama City University.

PMID: 21677484

Abstract

The clinical efficacy and safety of CPT-11+CDDP therapy were studied retrospectively in 34 patients with advanced and recurrent gastric cancer. The overall response rate was 5. 9%; MST was 209 days. The adverse effects observed were grade 3 in 7 patients(20. 6%). CPT-11+CDDP therapy could be useful and safe as third-line chemotherapy.

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Camptothecin / administration & dosage
Camptothecin / adverse effects
Camptothecin / analogs & derivatives*
Camptothecin / therapeutic use
Cisplatin / administration & dosage
Cisplatin / adverse effects
Cisplatin / therapeutic use*
Female
Humans
Irinotecan
Male
Middle Aged
Neoplasm Staging
Recurrence
Salvage Therapy*
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / pathology
Survival Rate

Substances

Irinotecan
Cisplatin
Camptothecin